The US Food and Drug Administration (FDA) has approved a generic drug developed by Taiwan-based TTY Biopharm Co Ltd (台灣東洋藥品) to treat acute promyelocytic leukemia (APL), the company said on Sunday.
The drug, arsenic trioxide, sold under the brand name Asadin, was first approved for medical use in the US last year, and is listed by the WHO as an essential medicine for treating APL.
APL, a rare form of acute myeloid leukemia (AML), is distinguished by there being too many immature blood-forming cells in the blood and bone marrow, which leads to a shortage of normal white and red blood cells in the body.
Photo: Chang Chia-ming, Taipei Times
It needs to be treated differently from other types of AML, and arsenic trioxide combined with all-trans retinoic acid has become the standard treatment for the cancer.
When APL was first identified in 1957, APL patients had a median survival rate of less than a week, but now 10-year survival rates are plausible thanks to improvements in diagnosis and medication.
TTY Biopharm said in a statement that it hoped the approval of its generic drug could help patients in the US.
The company first received a license to make the drug from the Taiwanese FDA in 2002. It was the first APL treatment license issued in Taiwan.
From 2018, the company developed the drug further under a milestone payment contract with another partner, which it did not identify.
The partner is responsible for the sale, licensing and approval of the TTY Biopharm’s generic drug in international markets, such as Malaysia, the Philippines, Thailand, the US and Vietnam.
The US FDA approval was the first received by TTY Biopharm for any of its drugs, and recognizes the company’s research and development capabilities and manufacturing strength, the company said.
As the materials used to make the drug are highly toxic, the company has partnered with National Central University to create a recycling technique for arsenic ions that makes wastewater from the drug production process safe to release.
In related news, TTY Biopharm’s board of directors yesterday approved the dismissal of general manager Shih Chun-liang (施俊良), after Shih admitted to being involved in an insider-trading scandal involving the company’s shares.
TTY Biopharm chairman Lin Chuan (林全) is also to act as general manager, the company said in a regulatory filing.
Additional reporting by Kao Shih-ching
soft landing: The US’ rate-setting FOMC finds itself in a difficult situation as it seeks to address inflation through interest rate hikes while avoiding a recession The US Federal Reserve is widely expected to hold interest rates steady on Wednesday after a summer of mixed economic data, while leaving the door open to another hike if needed. The Fed has raised interest rates 11 times over the past 18 months, lifting its key lending rate to a level not seen for 22 years as it tackles inflation still stubbornly above its long-term target of 2 percent. Analysts and traders broadly expect the US central bank to hold rates steady on Wednesday in order to give policymakers more time to assess the health of the world’s largest economy. “We think
AI TREND: TSMC has been rapidly expanding capacity to meet a spike in demand for advanced packaging services, but still expects supplies to be tight for 18 months Arizona is in talks with Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) about advanced chip packaging, state Governor Katie Hobbs said yesterday, which is crucial for the manufacturing of artificial intelligence (AI) chips. TSMC, which is building a US$40 billion chip factory in the US state, has not announced plans to build facilities for advanced chip packaging in the US. Advanced packaging processes stitch multiple chips together into a single device, lowering the added cost of more powerful computing. “Part of our efforts at building the semiconductor ecosystem is focusing on advanced packaging, so we have several things in the works around that
NXP Semiconductors NV expects its first automotive-grade 5-nanometer chip built by Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) to become available for automakers within one-and-a-half years at the earliest, following demand for better computing performance and energy efficiency for connected vehicles, a company executive said yesterday. That would mean a significant upgrade from the 16-nanometer technology NXP adopted in its existing series of microprocessors. NXP chief technology executive Lars Reger made the remarks during a media briefing yesterday in Taipei. The latest updates came after NXP unveiled its plan to source 5-nanometer capacity from TSMC in 2021. This is Reger’s first trip to
Tailwinds: Blockbuster earnings at Nvidia Corp have sparked hopes of a tech sector boom; Taiwanese chipmakers are hopeful benefits will come to them too The worst could be over for the New Taiwan dollar as China’s economic recovery and a rebound in the chip industry will support the beleaguered currency, analysts said. The NT dollar is on course to weaken for a sixth month, the longest stretch since 2006, after foreign funds turned sour on its technology sector and risk sentiment deteriorated on slower growth in China. The tide seems to be turning now on nascent signs of stabilization in China’s economy — its biggest trading partner — following policy boosts. The yuan emerged as the best-performing Asian currency last week, followed by the Japanese yen
RSS